Transtelephonic monitoring and transmission of stored XXXX detection and therapy data from an implantable cardioverter defibrillator.

@entity1 @entity1479 @entity1165 @entity1163 @entity737 @entity2224 @entity955 @entity943 @entity7129
A new transtelephonic monitoring device designed for use with @entity737 ( @entity737 ) was evaluated. It is capable of interrogating @entity737 and transmitting the following data via telephone: programmed parameters (e.g., @entity1165 [ @entity1165 ] and @entity2224 [ @entity2224 ] detection, therapies), number of @entity1165 and @entity2224 episodes, identification of successful therapies, the 20 cycle lengths preceding the last episode detected, the 10 cycle lengths after the last delivered therapy, battery voltage, and real-time transmission of the @entity1 's rhythm. Eighteen @entity1 (mean age 64 +/- 17 years; 15 males) were implanted with an @entity1479 and epicardial lead system. The @entity1 who did not live near the primary hospital were provided with this transmitter and instructed to transmit monthly and whenever @entity1163 , @entity1163 , or a shock were experienced. Five hundred ten episodes of spontaneous @entity943 (495 @entity1165 , 15 @entity2224 ) were detected in 14 of 18 @entity1 in a 24-month period and the success of each therapy (antitachycardia pacing, cardioversion 0.4-34 J, defibrillation 34 J) was analyzed. The number of therapies delivered and their success (%) in terminating the @entity943 were: 380 ramp/86%, 116 burst/84%, 119 cardioversion/57%, and 15 defibrillations/100%. Sixty-three (42%) of the 152 transmissions indicated an @entity943 . Twenty-five (16%) of the 152 were transmitted because of symptoms. Sixteen (9.7%) of 165 @entity1165 episodes could not be terminated by the full set of programmed @entity1165 therapies. Analysis of the pre- and post-episode intervals along with the @entity1 's transmitted rhythm indicated that @entity7129 or @entity955 were likely responsible for these episodes.(ABSTRACT TRUNCATED AT 250 WORDS)
